- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01171391
VA106483 Dose Response in Females
An Open Label, Dose Escalation Study to Assess Intra-Subject Dose Response to VA106483 in Female Subjects
Study Overview
Detailed Description
Nocturia, defined as waking to void at least once per night between periods of sleep, is a common complaint and shows an age-dependent increase in both prevalence and severity (number of nocturnal voids). The most common causes are detrusor over-activity, reduced nighttime functional bladder capacity, and nocturnal polyuria.
VA106483 is a selective vasopressin V2-receptor agonist in development for nocturia. VA106483 is a non-peptide drug that displays much improved oral availability over desmopressin and low dependence on glomerular filtration for its elimination.
VA106483 has been administered to 184 subjects (including healthy adult subjects [males and females], children [males and females] with nocturia and 48 elderly males [aged 65 years and over]). It has been administered as single doses both intravenously, up to doses of approximately 250 mg and orally up to 50 mg It is also being investigated in approximately 123 male subjects (two-thirds on active medication, one third on placebo) with nocturia in a current study with dosing for up to 8 weeks.
This intra-subject dose escalation study has previously been conducted in 10 elderly male subjects to determine whether subjects demonstrated a dose-dependent pharmacokinetic and pharmacodynamic (urine osmolality and diuresis) response and whether the dose of VA106483 could be titrated within an individual patient to achieve optimal clinical response in clinical practice. Given that to date, only 8 females have been exposed to VA106483, the purpose of this study is to confirm that the described duration of pharmacokinetics and pharmacodynamics of VA106483 in males is similar in females.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Kansas
-
Overland Park, Kansas, United States, 66211
- Quintiles Phase I Services
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female subjects 40 years and above
- BMI 18 to 32 kg/m2
- Using adequate contraception and providing negative pregnancy tests pre-dose
- In good health as determined by medical history and screening tests
- Subject is willing and able to abstain from alcohol and caffeine-containing food and beverages 72 hours prior to dosing and throughout the study
- Provide written, informed consent
Exclusion Criteria:
- Pregnancy or lactation
- Evidence of serious pathology or diseases including heart, hormone, liver and kidney, psychiatric and neurological problems, including syndrome of inappropriate antidiuretic hormone secretion, polydipsia or diabetes insipidus
- Likely to be hypersensitive to VA106483
- History of any relevant allergy
- Participation in a clinical study within 30 days
- Donation of blood (500 mL) within 60 days prior to dosing
- A history of alcohol abuse or drug addiction
- Positive results for HIV, HBV or HCV or drugs of abuse
- Currently taking any diuretics or clinically significant cytochrome 3A4 inhibitors or inducers
- Use of any non-prescription preparation within 72 hours prior to dosing, with the exception of ibuprofen, and acetaminophen used at recommended doses
- Treatment within the previous 3 months of drugs known to have a well defined potential for hepatoxicity
- Current smokers or recent ex-smokers
- Other protocol defined eligibility criteria may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Sugar pill
|
Placebo on Day 1
|
Experimental: VA106483 1mg
|
1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
|
Experimental: VA106483 2mg
|
1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
|
Experimental: VA106483 4mg
|
1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics
Time Frame: 10 days
|
VA106483 plasma concentration pre-dose over a 24hr post-dose period to assess pharmacokinetics of each dose level
|
10 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacodynamics
Time Frame: 10 days
|
Urine volume and osmolality
|
10 days
|
Safety and Tolerability
Time Frame: 10 days
|
AEs, laboratory safety tests, vital signs and ECG, physical examination.
|
10 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ralph Schutz, Quintiles Phase I Services
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 483-007
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nocturia
-
Winthrop University HospitalCompleted
-
Sanwa Kagaku Kenkyusho Co., Ltd.CompletedNocturia Due to Nocturnal PolyuriaJapan
-
Ferring PharmaceuticalsCompletedNocturia Associated With Nocturnal PolyuriaGermany
-
Wellesley Pharmaceuticals, LLCCompleted
-
Ferring PharmaceuticalsCompletedNocturiaUnited States
-
Corporacion Parc TauliCompleted
-
Ferring PharmaceuticalsCompleted
-
Cognitive Research CorporationNovartis PharmaceuticalsWithdrawn
Clinical Trials on VA106483
-
Vantia LtdVeeda Clinical ResearchCompleted
-
Vantia LtdCompletedNocturia | Benign Prostatic Hypertrophy (BPH)Germany
-
Vantia LtdCompleted